View Filing Data

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2019	Feb. 28, 2020
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Registrant Name	ACURA PHARMACEUTICALS, INC
Entity Central Index Key	0000786947
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	ACUR
Entity Common Stock, Shares Outstanding		21,650,294

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Assets:
Cash	$ 615	$ 91
Royalty receivable	171	137
Collaboration revenue receivable from related party	10	0
Prepaid expenses and other current assets	185	166
Income tax receivable	34	67
Total current assets	1,015	461
Income tax receivable	34	68
Property, plant and equipment, net (Note 6)	555	606
Intangible asset, net of accumulated amortization of $1,138 and $983 (Note 3)	862	1,017
Total assets	2,466	2,152
Liabilities:
Accounts payable	330	605
Accrued expenses (Note 7)	685	596
Other current liabilities	29	11
Sales returns liability	223	223
Total current liabilities	1,267	1,435
Convertible debt to related party, net of discounts (Note 8)	6,000	4,224
Accrued interest to related party (Note 8)	116	110
Total liabilities	7,383	5,769
Commitments and contingencies (Note 15)
Stockholders' deficit:
Common stock - $0.01 par value per share; 100,000 shares authorized, 21,300 and 21,034 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	213	210
Additional paid-in capital	383,021	380,395
Accumulated deficit	(388,151)	(384,222)
Total stockholders' deficit	(4,917)	(3,617)
Total liabilities and stockholders' deficit	$ 2,466	$ 2,152

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenues:
Royalties	$ 172	$ 73	$ 285	$ 347
Collaboration	102	0	102	0
License fees	1,050	0	1,050	0
Total revenues	1,324	73	1,437	347
Expenses:
Research and development	465	549	1,040	1,676
General and administrative	548	543	1,391	2,332
Total expenses	1,013	1,092	2,431	4,008
Operating income (loss)	311	(1,019)	(994)	(3,661)
Loss on debt extinguishment	0	0	(2,600)	0
Interest expense, net (Note 10)	(111)	(76)	(335)	(189)
Income (loss) before income taxes	200	(1,095)	(3,929)	(3,850)
Provision for income taxes	0	0	0	0
Net income (loss)	$ 200	$ (1,095)	$ (3,929)	$ (3,850)
Net income (loss) per share:
Basic	$ 0.00	$ (0.05)	$ (0.16)	$ (0.18)
Diluted	$ 0.00	$ (0.05)	$ (0.16)	$ (0.18)
Weighted average number of shares outstanding:
Basic	31,593	21,168	25,023	21,101
Diluted	31,593	21,168	25,023	21,101

CONSOLIDATED STATEMENT OF CHANGES IN ACCUMULATED STOCKHOLDERS' DEFICIT - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2017	$ 208	$ 380,145	$ (380,380)	$ (27)
Balance (in shares) at Dec. 31, 2017	20,796
Net loss			(1,494)	(1,494)
Non-cash share-based compensation		62		62
Net distribution of common stock pursuant to restricted stock unit award plan	$ 2	32		34
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)	238
Balance at Mar. 31, 2018	$ 210	380,239	(381,874)	(1,425)
Balance (in shares) at Mar. 31, 2018	21,034
Balance at Dec. 31, 2017	$ 208	380,145	(380,380)	(27)
Balance (in shares) at Dec. 31, 2017	20,796
Net loss				(3,850)
Balance at Sep. 30, 2018	$ 210	380,351	(384,230)	(3,669)
Balance (in shares) at Sep. 30, 2018	21,034
Balance at Dec. 31, 2017	$ 208	380,145	(380,380)	(27)
Balance (in shares) at Dec. 31, 2017	20,796
Net loss				(3,840)
Balance at Dec. 31, 2018	$ 210	380,395	(384,222)	(3,617)
Balance (in shares) at Dec. 31, 2018	21,034
Balance at Mar. 31, 2018	$ 210	380,239	(381,874)	(1,425)
Balance (in shares) at Mar. 31, 2018	21,034
Net loss			(1,261)	(1,261)
Non-cash share-based compensation		60		60
Balance at Jun. 30, 2018	$ 210	380,299	(383,135)	(2,626)
Balance (in shares) at Jun. 30, 2018	21,034
Net loss			(1,095)	(1,095)
Non-cash share-based compensation		52		52
Balance at Sep. 30, 2018	$ 210	380,351	(384,230)	(3,669)
Balance (in shares) at Sep. 30, 2018	21,034
Balance at Dec. 31, 2018	$ 210	380,395	(384,222)	(3,617)
Balance (in shares) at Dec. 31, 2018	21,034
Net loss			(788)	(788)
Non-cash share-based compensation		29		29
Net distribution of common stock pursuant to restricted stock unit award plan	$ 3	12		15
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)	266
Balance at Mar. 31, 2019	$ 213	380,436	(385,010)	(4,361)
Balance (in shares) at Mar. 31, 2019	21,300
Balance at Dec. 31, 2018	$ 210	380,395	(384,222)	(3,617)
Balance (in shares) at Dec. 31, 2018	21,034
Net loss				(3,929)
Balance at Sep. 30, 2019	$ 213	383,021	(388,151)	(4,917)
Balance (in shares) at Sep. 30, 2019	21,300
Balance at Mar. 31, 2019	$ 213	380,436	(385,010)	(4,361)
Balance (in shares) at Mar. 31, 2019	21,300
Net loss			(3,341)	(3,341)
Non-cash share-based compensation		29		29
Debt premium from debt modification		1,382		1,382
Issuance of warrant		1,145		1,145
Balance at Jun. 30, 2019	$ 213	382,992	(388,351)	(5,146)
Balance (in shares) at Jun. 30, 2019	21,300
Net loss			200	200
Non-cash share-based compensation		29		29
Balance at Sep. 30, 2019	$ 213	$ 383,021	$ (388,151)	$ (4,917)
Balance (in shares) at Sep. 30, 2019	21,300

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash Flows from Operating Activities:
Net loss	$ (3,929)	$ (3,850)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	51	56
Non-cash share-based compensation	87	174
Capitalized debt discount	(13)	(103)
Amortization of debt discount and deferred debt issuance costs	66	59
Amortization of intangible asset	155	155
Loss on debt extinguishment	2,600	0
Loss on disposal of equipment	1
Changes in assets and liabilities:
Royalty receivable	(34)	(37)
Collaboration revenue receivable from related party	(10)
Prepaid expenses and other current assets	(19)	26
Income taxes refundable	67
Refundable retainer deposits		(80)
Accounts payable	(275)	778
Accrued expenses	89	11
Accrued interest on loan		120
Accrued interest on related party loans	6
Other current liabilities	18	6
Net cash used in operating activities	(1,140)	(2,685)
Cash Flows from Financing Activities:
Proceeds from distribution of restricted stock units	14	2
Proceeds from related party loans	1,650	2,200
Principal payments on loan		(1,719)
Net cash provided by financing activities	1,664	483
Net increase (decrease) in cash	524	(2,202)
Cash at beginning of period	91	2,220
Cash at end of period	$ 615	18
Supplemental disclosure of cash flow information:
Cash interest payments on loan		$ 112

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands		9 Months Ended
	Jun. 28, 2019	Sep. 30, 2019	Sep. 30, 2018
Related party loans made to Company	$ 5,000	$ 5,000
Imputed interest on the below market rate recorded as benefit to interest income			$ 1,500
Loss on debt extinguishment	(2,600)	(2,600)	0
Common stock purchase warrant issued to the related party lender	1,150
Excess fair value premium on the newly issued convertible debt	1,380
Write-off of unamortized debt discount	70		74
Accrued interest due on the related party loan rolled into principal under modifications	274	116
Proceeds from related party loan receivable	$ 725	1,650	$ 2,200
Interest Rate Below Market Reduction [Member]
Related party loans made to Company		650
Imputed interest on the below market rate recorded as benefit to interest income		$ 13

OPERATIONS AND BASIS OF PRESENTATION

9 Months Ended

Sep. 30, 2019

OPERATIONS AND BASIS OF PRESENTATION

OPERATIONS AND BASIS OF PRESENTATION

NOTE 1 – OPERATIONS AND BASIS OF PRESENTATION

Principal Operations

Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “Acura”, “We”, “Us” or “Our”) is an innovative drug delivery company engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Limitx™ Technology is intended to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidently or purposefully ingested. Our Aversion® Technology is intended to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Our Impede® Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.

Our Limitx Technology is in development with immediate-release tablets containing hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidate due to its large market size and its known prevalence of oral excessive tablet abuse and overdose. The technology is designed to retard the release of active opioid drug when too many tablets are accidentally or purposefully ingested by neutralizing stomach acid with buffer ingredients but deliver efficacious amounts of drug when taken as a single tablet with a nominal buffer dose. US commercialization rights to LTX-03 are licensed to Abuse Deterrent Pharma LLC (See Note 3).

Our Aversion Technology has been licensed to Zyla Life Sciences or Zyla (formerly known as Egalet Corporation) for use in Oxaydo® Tablets (oxycodone HCl, CII), and is the first approved immediate-release oxycodone product in the United States with abuse deterrent labeling. Oxaydo is currently approved by the FDA for marketing in the United States in 5mg and 7.5mg strengths (See Note 3).

Our Impede Technology is used in Nexafed® Tablets (30mg pseudoephedrine HCl) and Nexafed® Sinus Pressure + Pain Tablets (30/325mg pseudoephedrine HCl and acetaminophen). We have licensed to MainPointe Pharmaceuticals, LLC (MainPointe), our Impede Technology in the United States and Canada to commercialize these Nexafed products (See Note 3).

Basis of Presentation, Liquidity and Substantial Doubt in Going Concern

The accompanying unaudited consolidated financial statements of the Company have been prepared assuming the Company will continue as a going concern and in accordance with generally accepted accounting principles in the United States of America for interim financial information, the instructions to Form 10‑Q and Article 10 of Regulation S-X. Accordingly, they do not contain all disclosures required by generally accepted accounting principles. Reference should be made to the Company’s Annual Report on Form 10‑K for the year ended December 31, 2018. In the opinion of the Company, all normal recurring adjustments have been made that are necessary to present fairly the results of operations for the interim periods. Operating results for the three and nine month periods ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019.

The going concern basis of presentation assumes that we will continue in operation one year after the date these financial statements are issued and we will be able to realize our assets and discharge our liabilities and commitments in the normal course of business. As of September 30, 2019, we had cash of $615 thousand, working capital deficit of $252 thousand and an accumulated deficit of $388 million. We had a loss from operations of $994 thousand and a net loss of $3.9 million for the nine months ended September 30, 2019. We have suffered recurring losses from operations and have not generated positive cash flows from operations. We had a loss from operations of $3.92 million and a net loss of $3.84 million for the year ended December 31, 2018. We anticipate operating losses to continue for the foreseeable future. As of February 28, 2020 we had cash of approximately $1.0 million.

On June 28, 2019, we entered into with Abuse Deterrent Pharma, LLC (“AD Pharma”), a License, Development and Commercialization Agreement (the "AD Pharma Agreement"). AD Pharma has the right to terminate the AD Pharma Agreement for "convenience on 30 days prior written notice". Under the AD Pharma Agreement, the required monthly license payments by AD Pharma will only continue until November 2020 if AD Pharma does not exercise their right to terminate the AD Pharma Agreement. To fund further operations beyond December 2020, we must raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies or explore a variety of capital raising and other transactions to provide additional funding. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. In the absence of such financing or third-party license or collaboration agreements, there will be substantial doubt about the Company's ability to continue as a going concern and the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. Delay or cessation of the Company's continuing product development efforts will have a material adverse effect on the Company's financial condition and results of operations. Should AD Pharma exercise their right to terminate the AD Pharma Agreement, we would need to raise additional financing or enter into license or collaboration agreements with third parties relating to our technologies. No assurance can be given that we will be successful in obtaining any such financing or in securing license or collaboration agreements with third parties on acceptable terms, if at all, or if secured, that such financing or license or collaboration agreements will provide payments to the Company sufficient to fund continued operations. In the absence of such financing or third-party license or collaboration agreements, the Company will be required to scale back or terminate operations and/or seek protection under applicable bankruptcy laws. An extended delay or cessation of the Company’s continuing product development efforts will have a material adverse effect on the Company’s financial condition and results of operations. In light of AD Pharma's right to terminate the Agreement for "convenience on 30 days prior written notice", our auditors included in their report relating to our 2018 financial statements a "going concern" explanatory paragraph as to substantial doubt on our ability to continue as a going concern.

In view of the matters described above, management has concluded that substantial doubt exists with respect to the Company’s ability to continue as a going concern within one year after the date the financial statements are issued. The recoverability of a major portion of the recorded asset amounts shown in the Company’s accompanying consolidated balance sheets is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its funding requirements on a continuous basis, to maintain existing financing and to succeed in its future operations. The Company’s financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

LICENSE AND COLLABORATION AGREEMENTS	9 Months Ended
LICENSE AND COLLABORATION AGREEMENTS	Sep. 30, 2019
LICENSE AND COLLABORATION AGREEMENTS
LICENSE AND COLLABORATION AGREEMENTS	NOTE 3 – LICENSE AND COLLABORATION AGREEMENTS The Company’s revenues are comprised of amounts earned under its license and collaboration agreements and royalties. Revenue recognition occurs when a customer obtains control of promised services in an amount that reflects the consideration the Company expects to receive in exchange for those services based on a short-term credit arrangement. AD Pharma Agreement covering LTX-03 On June 28, 2019 we entered into with Abuse Deterrent Pharma, LLC ("AD Pharma"), a License, Development and Commercialization Agreement (the "AD Pharma Agreement"), for the development and license of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura's patented LIMITx(TM). Acura will receive a monthly license payment of $350 thousand by AD Pharma for 18 months until November 2020. The first license payment was received July 2, 2019. AD Pharma will pay for and reimburse Acura for all outside development costs on LTX-03. If the NDA filing for LTX-03 is not accepted by the FDA within 18 months, AD Pharma may terminate the AD Pharma Agreement and take ownership of the Limitx intellectual property. AD Pharma does have the right to terminate the AD Pharma Agreement anytime for "convenience on 30 days prior written notice". AD Pharma retains commercialization rights from which Acura will receive stepped royalties on sales and potential sales related milestones. We also granted authority to MainPointe Pharmaceuticals, LLC (MainPointe) to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength. (See MainPointe Agreement covering Nexafed products). The Option Product exercise price of $500 thousand is waived if the exercise of the option occurs by June 28, 2024 (five years from the effective date of the AD Pharma Agreement). On June 28, 2019 Mr. John Schutte assigned and transferred to AD Pharma his $6.0 million promissory note, the common stock purchase warrant for 10.0 million common shares, and the security agreement granting a security interest in all of the Company's assets. (See Note 8). Mr. Schutte is our largest shareholder and directly owns approximately 47.5% of our common stock (after giving effect to the exercise of remaining common stock purchase warrants he holds). Mr. Schutte controls MainPointe and is the principal investor in AD Pharma. Zyla Agreement covering Oxaydo In April 2014, we terminated an agreement with Pfizer and the return to us of Aversion Oxycodone (formerly known as Oxecta®) and all Aversion product rights in exchange for a one-time termination payment of $2.0 million. Our termination payment of $2.0 million has been recorded in our financial statements as an intangible asset and is being amortized over the remaining useful life of the patent covering Aversion Oxycodone, which was 9.7 years as of the date the agreement was terminated. Amortization of the patent for the years 2019 through 2021 is expected to approximate $208 thousand each year and $52 thousand be quarter. In January 2015, we and Zyla US, Inc. and Zyla Ltd., each a subsidiary of Zyla Corporation, or collectively Zyla, entered into a Collaboration and License Agreement (the “Zyla Agreement”) to commercialize Aversion Oxycodone (formerly known as Oxecta®) under our tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Zyla Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Zyla and Zyla is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015. In accordance with the Zyla Agreement, we and Zyla formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions although no meetings were held in 2019 or to date in 2020. Zyla is responsible for the fees and expenses relating to the Oxaydo NDA and product line extensions of Oxaydo, provided that Zyla will pay a substantial majority of the fees and expenses and we will pay for the remaining fees and expense relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States. Zyla will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Zyla is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Zyla will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Zyla may develop Oxaydo for other countries and in additional strengths, in its discretion. Zyla paid us a $5.0 million license fee upon signing of the Zyla Agreement and on October 9, 2015, paid us a $2.5 million milestone in connection with the first commercial sale of Oxaydo. We will be entitled to a one-time $12.5 million sales-based milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. We are receiving from Zyla a stepped royalty at percentage rates ranging from mid-single digits to double-digits based on Oxaydo net sales during each calendar year (excluding net sales resulting from our co-promotion efforts). In any calendar year of the agreement in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Zyla's royalty payment obligations commence on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo). Royalties will be reduced upon the entry of generic equivalents, as well as for payments required to be made by Zyla to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor. The Zyla Agreement expires upon the expiration of Zyla’s royalty payment obligations in all countries. Either party may terminate the Zyla Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Zyla Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Zyla Agreement with respect to the U.S. and other countries if Zyla materially breaches its commercialization obligations. Zyla may terminate the Zyla Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Zyla’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Zyla Agreement provides for the transition of development and marketing of Oxaydo from Zyla to us, including the conveyance by Zyla to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Zyla’s supply of Oxaydo for a transition period. MainPointe Agreement covering Nexafed products and assignment thereof to AD Pharma In March 2017, we and MainPointe entered into the MainPointe Agreement, pursuant to which we granted MainPointe an exclusive license to our Impede technology to commercialize both of our Nexafed and Nexafed Sinus Pressure + Pain product (“Nexafed products”) in the U.S. and Canada. We also conveyed to MainPointe our existing inventory and equipment relating to our Nexafed products. MainPointe is responsible for all development, manufacturing and commercialization activities with respect to products covered by the Agreement. On signing the MainPointe Agreement, MainPointe paid us an upfront licensing fee of $2.5 million. The MainPointe Agreement also provides for our receipt of a 7.5% royalty on net sales of the licensed products. The royalty payment for each product will expire on a country-by-country basis when the Impede® patent rights for such country have expired or are no longer valid; provided that if no Impede patent right exists in a country, then the royalty term for that country will be the same as the royalty term for the United States. After the expiration of a royalty term for a country, MainPointe retains a royalty free license to our Impede® technology for products covered by the Agreement in such country. MainPointe has the option to expand the licensed territory beyond the United States and Canada to the European Union (and the United Kingdom), Japan and South Korea for payments of $1.0 million, $500 thousand and $250 thousand, respectively. In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate. On June 28, 2019, we granted authority to MainPointe to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength. The Option Product exercise price of $500 thousand is waived if the exercise of the option occurs by June 28, 2024 (five years from the effective date of the AD Pharma Agreement). The MainPointe Agreement may be terminated by either party for a material breach of the other party, or by Acura if MainPointe challenges certain of its patents. Upon early termination of the MainPointe Agreement, MainPointe’s licenses to the Impede technology and all products will terminate. Upon termination, at Acura’s request the parties will use commercially reasonable efforts to transition the Nexafed® and Nexafed® Sinus Pressure + Pain products back to Acura. On January 1, 2020, MainPointe assigned to AD Pharma, with Acura's consent, all of its right, title and interest in the MainPointe Agreement between MainPointe and Acura dated March 16, 2017. KemPharm Agreement Covering Certain Opioid Prodrugs In October 2016, we and KemPharm Inc. (”KemPharm”) entered into a worldwide License Agreement (the “KemPharm Agreement”) pursuant to which we licensed our Aversion® technology to KemPharm for its use in the development and commercialization of three products using 2 of KemPharm’s prodrug candidates. KemPharm has also been granted an option to extend the KemPharm Agreement to cover two additional prodrug candidates. KemPharm is responsible for all development, manufacturing and commercialization activities. Upon execution of the KemPharm Agreement, KemPharm paid us an upfront payment of $3.5 million. If KemPharm exercises its option to use our Aversion technology with more than the two licensed prodrugs, then KemPharm will pay us up to $1.0 million for each additional prodrug license. In addition, we will receive from KemPharm a low single digit royalty on commercial sales by KemPharm of products developed using our Aversion technology under the KemPharm Agreement. KemPharm’s royalty payment obligations commence on the first commercial sale of a product using our Aversion technology and expire, on a country-by-country basis, upon the expiration of the last to expire patent claim of the Aversion technology covering a product in such country, at which time the license for the particular product and country becomes fully paid and royalty free. The KemPharm Agreement expires upon the expiration of KemPharm’s royalty payment obligations in all countries. Either party may terminate the KemPharm Agreement in its entirety if the other party materially breaches the KemPharm Agreement, subject to applicable cure periods. Acura or KemPharm may terminate the KemPharm Agreement with respect to the U.S. and other countries if the other party challenges the patents covering the licensed products. KemPharm may terminate the KemPharm Agreement for convenience on ninety (90) days prior written notice. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the KemPharm Agreement provides for termination of our license grant to KemPharm.

REVENUE FROM CONTRACTS WITH CUSTOMER

9 Months Ended

Sep. 30, 2019

REVENUE FROM CONTRACTS WITH CUSTOMER

REVENUE FROM CONTRACTS WITH CUSTOMER

NOTE 4 – REVENUE FROM CONTRACTS WITH CUSTOMER

Adoption of ASC Topic 606, Revenue from Contracts with Customers

The Company adopted ASC Topic 606 on January 1, 2018 applying the modified retrospective method to all contracts that were not completed as of January 1, 2018. While the timing of future revenues under ASC Topic 606 may differ from the Company’s historical accounting practices under ASC Topic 605, the cumulative effect recorded through the Consolidated Statement of Stockholders’ Deficit was zero because there was no change in timing or measurement of revenues for open contracts at January 1, 2018.

Under ASC 606, revenue is recognized when, or as, performance obligations under terms of a contract are satisfied, which occurs when control of the promised service is transferred to a customer. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring services to a customer (“transaction price”). The Company will then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when, or as, the performance obligation is satisfied. When determining the transaction price of the contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. None of the Company’s licenses and collaboration agreements contained a significant financing component at September 30, 2019.

The Company’s existing license and collaboration agreements may contain a single performance obligation or may contain multiple performance obligations. Those which contain multiple performance obligations will require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised services underlying each performance obligation.

The Company’s existing license and collaboration agreements contain customer options for the license of additional products and territories. We determined the option’s standalone selling prices based on the option product’s potential market size in the option territory as compared to the currently licensed product and U.S. territory. Some of our existing license and collaboration agreements contain a license to the technology as well as licenses to tradenames or trademarks. The Company determined that the licenses to the tradenames or trademarks were immaterial in context of the contract.

Sales-based Milestones and Royalty Revenues

The commercial sales-based milestones and sales royalties earned under the license and collaboration for Oxaydo and sales royalties earned under the license for the Nexafed products, are recorded in the period of the related sales by Zyla and MainPointe. Payments of sales-based milestones are generally due within 30 days after the end of a calendar year. Payments of royalties are generally due within 45 days after the end of a calendar quarter.

License and Collaboration Agreement Revenues

The achievement of milestones under the Company’s license and collaboration agreements will be recorded during the period the milestone’s achievement becomes probable, which may result in earlier recognition as compared to the previous accounting standards. The license fee of an option product or option territory under the Company’s license and collaboration agreements will be recorded when the option is exercised and any obligations on behalf of the Company, such as to transfer know-how, has been fulfilled, which may result in later recognition as compared to the previous accounting standards.

Disaggregation of Total Revenues

The Company has two licenses for currently marketed products containing its technologies; the Nexafed products containing the Impede Technology to MainPointe and Oxaydo containing the Aversion Technology to Zyla. All of the Company’s royalty revenues are earned from these two licenses and from the licensee’s sale of products in the U.S.

On June 28, 2019 we entered into an agreement with AD Pharma for the development and license of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura's patented LIMITx(TM) having a monthly license payment of $350 thousand by AD Pharma for 18 months until November 2020. The first license payment was received July 2, 2019.

Royalty revenues by licensee are summarized below:


	Three months				Nine months
	Ended				Ended
	September 30,				September 30,
	(In thousands)				(In thousands)
	2019		2018		2019		2018
Egalet	$	171	$	70	$	269	$	330
MainPointe		1		3		16		17
Royalty revenues	$	172	$	73	$	285	$	347

Contract Balance and Performance Obligations

The Company had no contract assets and contract liability balances under the license and collaboration agreements at either September 30, 2019 or December 31, 2018. Contract assets may be reported in future periods under prepaid expenses or other current assets on the balance sheet. Contract liabilities may be reported in future periods consisting of deferred revenue as presented on the balance sheet.

PROPERTY, PLANT AND EQUIPMENT

9 Months Ended

Sep. 30, 2019

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT

NOTE 6 – PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at September 30, 2019 and December 31, 2018 are summarized as follows:


	September 30,		December 31,
	2019		2018
	(in thousands)
Building and improvements	$	1,273	$	1,273
Scientific equipment		598		598
Computer hardware and software		107		107
Machinery and equipment		275		275
Land and improvements		162		162
Other personal property		70		70
Office equipment		27		27
Total		2,512		2,512
Less: accumulated depreciation		(1,957)		(1,906)
Net property, plant and equipment	$	555	$	606

We do not have leasehold improvements nor do we have capitalized leases. Costs of betterments are capitalized while maintenance costs and repair costs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation will be removed from the respective accounts.

Depreciation expense was $51 thousand and $56 thousand for the nine month periods ended September 30, 2019 and 2018, respectively and was $17 thousand and $18 thousand for the three month periods ended September 30, 2019 and 2018. The Company leases administrative office space in Palatine, Illinois on a month to month basis at the rate of approximately $2 thousand per month.

DEBT

9 Months Ended

Sep. 30, 2019

DEBT

DEBT

NOTE 8 – DEBT

Fully Paid Loan

In December 2013, we entered into a Loan and Security Agreement (the “Oxford Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $10.0 million (the “Term Loan”). In October 2018 we borrowed $1.8 million from Mr. Schutte and used $1.5 million from the loan proceeds to negotiate, settle and pay-off in full the Oxford Loan for $1.5 million. We recognized a net gain of $296 thousand on the debt settlement. All security interests of Oxford with respect to the Oxford Term Loan have been released.

The Oxford Term Loan accrued interest at a fixed rate of 8.35% per annum (with a default rate of 13.35% per annum). The Company was required to make monthly interest−only payments until April 1, 2015 (“Amortization Date”) and on the Amortization Date, the Company began to make payments of principal and accrued interest in equal monthly installments of $260 thousand sufficient to amortize the Term Loan through the maturity date of December 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loan was due and payable in full on December 1, 2018. As security for its obligations under the initial Oxford Loan Agreement (prior to the Third Amendment), the Company granted Lender a security interest in substantially all of its existing and after−acquired assets, exclusive of its intellectual property assets. Upon the execution of the Oxford Loan Agreement, we issued to the Lender warrants to purchase an aggregate of up to 60 thousand shares of our common stock at an exercise price equal to $7.98 per share (after adjustment for our one-for-five reverse stock split) (the “Warrants”). We recorded $400 thousand as debt discount associated with the relative fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire December 27, 2020.

In January 2015, we and Oxford amended the Oxford Loan Agreement providing for the exercise price of the Warrants to be lowered from $7.98 to $2.52 per share (the average closing price of our common stock on Nasdaq for the 10 trading days preceding the date of the amendment and after giving effect to our one-for-five reverse stock split) and we recorded additional debt discount of $33 thousand representing the fair value of the Warrant modification.

The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $50 thousand and the Lender’s expenses, in connection with the Oxford Loan Agreement. Combined with the Company’s own expenses and a $100 thousand consulting placement fee, the Company incurred a total $231 thousand in deferred debt issue costs. We have amortized these costs, including debt modification additional costs, into interest expense over the term of the Term Loan using the loan’s effective interest rate of 10.16%.

Related Party Convertible Loan

From January 1, 2019 and through June 27, 2019, we borrowed an aggregate of $650 thousand from Mr. Schutte and issued various promissory notes to him with the same terms and conditions from the previous loans. Because we believed the Schutte Notes’ rate of interest is below current market rates for us, we imputed interest on the below market rate element of the loans using the 10.16% interest rate under the Oxford Loan Agreement and this has aggregated to $185 thousand as of June 27, 2019. We recorded these benefits to interest income in the period we received the loan, with a corresponding like amount as debt discount against the principal amount of the loan. The debt discount will be amortized to interest expense over the term on the loans. All our assets are pledged as collateral under the Schutte Notes, including our intellectual property.

On June 27, 2019 the aggregate amount of the loans made to the Company by Mr. Schutte aggregated $5.0 million. On June 28, 2019 we entered into an agreement to borrow an additional $725 thousand from Mr. Schutte, which was received on July 2, 2019, bringing the aggregate principal of the loans and accrued interest to $6.0 million, and consolidated the loans into a single promissory note with a fixed interest rate of 7.5%, maturity date of July 1, 2023, granted principal and interest conversion rights into shares of our common stock at a price of $0.16 per share, issued a warrant for 10.0 million common shares having an exercise price of $0.01 per share, and granted a security interest in all of the Company’s assets, which includes our intellectual property. The principal amount of the loan is convertible into 37.5 million shares of our common stock. The modifications to the loan and the method of accounting for the loan changes resulted in a $2.6 million loss on debt extinguishment. The $6.0 million promissory note, the common stock purchase warrant and the security agreement were all assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019.

The events of default under the $6.0 million note are limited to bankruptcy defaults, failure to pay interest and principal when due on July 1, 2023 or upon the termination of the AD Pharma agreement covering LTX-03. The $6.0 million note may be prepaid at any time in whole or in part but only with the consent of the noteholder.

Our debt interest expense for the three and nine month months ended September 30, 2019 and 2018 consisted of the following:


	Three months Ended				Nine months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Interest expense:	(in thousands)				(in thousands)
Fully paid term loan	$	—	$	49	$	—	$	194
Related party term loans		111		29		279		37
Debt discount		—		22		66		46
Debt issue costs		—		3		—		13
Financed insurance premiums		—		2		3		2
Total interest expense	$	111	$	105	$	348	$	292
Less: imputed interest income on related party loan		—		(29)		(13)		(103)
Total interest expense, net	$	111	$	76	$	335	$	189

RELATED PARTY TRANSACTIONS

9 Months Ended

Sep. 30, 2019

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS

NOTE 9 – RELATED PARTY TRANSACTIONS

Private Placement with Mr. John Schutte

In July 2017, we completed a $4.0 million private placement with Mr. John Schutte (sometimes referred to as the “Investor”), consisting of 8,912,655 units (“Units”) of the Company, at a price of $0.4488 per Unit (the “Transaction”). Each Unit consists of one share of common stock and a warrant to purchase one fifth (0.2) of a share of common stock. The issue price of the Units was equal to 85% of the average last sale price of our common stock for the five trading days prior to completion of the Transaction. The warrants are immediately exercisable at a price of $0.528 per share (which equals the average last sale price of the Company’s common stock for the five trading days prior to completion of the Transaction) and expire five years after issuance (subject to earlier expiration in event of certain acquisitions). We have assigned a relative fair value of $495 thousand to the warrants out of the total $4.0 million proceeds from the private placement transaction and have accounted these warrants as equity. The Transaction was completed through a private placement to an accredited investor and was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, as amended and/or Regulation D promulgated under the Securities Act of 1933.

MainPointe Pharmaceuticals LLC

Investor is a principal of MainPointe Pharmaceuticals LLC, a Kentucky limited liability company ("MainPointe"). In March 2017, we granted MainPointe an exclusive license to our Impede Technology to commercialize our Nexafed® and Nexafed® Sinus Pressure + Pain Products in the United States and Canada for an upfront licensing fee of $2.5 million plus approximately $309 thousand for transferred inventory and equipment. The Company is receiving a 7.5% royalty on sales of licensed products. MainPointe also has options to expand the territory and products covered for additional sums. Included in the reported royalty revenue for the three months ended 2019 and 2018 is $3 thousand and $6 thousand, respectively and for the nine months ended 2019 and 2018 is $15 thousand and $14 thousand, respectively of royalty revenue from MainPointe (See Note 3). On January 1, 2020, MainPointe assigned to AD Pharma, with Acura's consent, all of its right, title and interest in the MainPointe Agreement between MainPointe and Acura.

As part of the closing of the Transaction, the Company and Essex Woodlands Health Ventures V, L.P. (“Essex”) and Galen Partners III, L.P. (“Galen”) amended and restated the existing Voting Agreement including such parties to provide for the Investor to join as a party (as so amended, the “Second Amended and Restated Voting Agreement”). The Second Amended and Restated Voting Agreement provides that our Board of Directors shall remain comprised of no more than seven members (subject to certain exceptions), (i) one of whom is the Company’s Chief Executive Officer, (ii) three of whom are independent under Nasdaq standards, and (iii) one of whom shall be designated by each of Essex, Galen and Investor, and the parties to such agreement would vote for such persons. The right of each of Essex, Galen and Investor to designate one director to our Board will continue as long as he or it and their affiliates collectively hold at least 600,000 shares of our common stock (including warrants exercisable for such shares). Immanuel Thangaraj is the designee of Essex. Investor has not designated a director as of the date of filing of this Report. Galen had not designated a director and lost that right in December 2017 when it disposed of its shares of common stock in the Company. Once such shareholder no longer holds such securities, the additional forfeited seat would become a seat for an independent director to thereafter be nominated to the Board of Directors from time to time by the then current directors and as applicable, to be elected by the directors to fill the vacancy created by the forfeited seat or submitted to the vote of shareholders at the Company’s next annual meeting. An independent director has not been named to fill the seat forfeited by Galen.

Loans with Mr. John Schutte

During the period January 1, 2019 through June 27, 2019 we borrowed an aggregate of $650 thousand from Mr. John Schutte. On June 28, 2019 we borrowed an additional $725 thousand from Mr. Schutte, bringing the aggregate principal of the loans and accrued interest to $6.0 million, and consolidated the loans into a single promissory note with a fixed interest rate of 7.5%, maturity date of July 1, 2023, granted conversion rights of principal and interest into shares of our common stock at a price of $0.16 per share, issued a warrant for 10.0 million common shares having an exercise price of $0.01 per share, and granted a security interest in all of the Company’s assets, which includes our intellectual property. The principal amount of the note is convertible into 37.5 million shares of our common stock. The $6.0 million promissory note, the common stock purchase warrant and the security agreement were all assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019.

AD Pharma Agreement covering LTX-03

On June 28, 2019, we entered into a License, Development and Commercialization Agreement (the "AD Pharma Agreement") with Abuse Deterrent Pharma, LLC (“AD Pharma”), a special purpose company representing a consortium of investors that will finance Acura’s operations and completion of development of LTX-03 (hydrocodone bitartrate with acetaminophen) immediate-release tablets utilizing Acura’s patented LIMITx™ technology which addresses the consequences of excess oral administration of opioid tablets, the most prevalent route of opioid overdose and abuse. The AD Pharma Agreement grants AD Pharma exclusive commercialization rights in the United States to LTX-03. Financial arrangements include:

Monthly license payments to Acura by AD Pharma of $350 thousand up to the earlier of 18 months or FDA’s acceptance of a New Drug Application (“NDA”) for LTX-03;

Reimbursement by AP Pharma of Acura’s LTX-03 outside development expenses;

Upon commercialization of LTX-03, Acura receives stepped royalties on sales and is eligible for certain sales related milestones; and

Acura authorizes MainPointe to assign to AD Pharma the option and the right to add, as an Option Product to the Nexafed® Agreement, a Nexafed® 12-hour dosage (an extended-release pseudoephedrine hydrochloride product utilizing the IMPEDE® Technology in 120mg dosage strength).

AD Pharma may terminate the AD Pharma Agreement at any time. Additionally, if the NDA for LTX-03 is not accepted by the FDA within 18 months, AD Pharma may terminate the AD Pharma Agreement and take ownership of the intellectual property. On July 2, 2019 we received the first monthly license payment of $350 thousand and have received monthly license payments in each of the subsequent months through February 2020.

COMMON STOCK WARRANTS

9 Months Ended

Sep. 30, 2019

COMMON STOCK WARRANTS

COMMON STOCK WARRANTS

NOTE 10 – COMMON STOCK WARRANTS

Our warrant activity for the nine months ended September 30, 2019 and 2018 consisted of the following (in thousands except price data):


	Nine Months Ended
	September 30,
	2019			2018
		WAvg			WAvg
		Exercise			Exercise
	Number	Price		Number	Price
Outstanding, Jan. 1	1,842	$	0.59	1,842	$	0.59
Issued	10,000		0.01	—		—
Exercised	—		—	—		—
Expired	—		—	—		—
Modification	—		—	—		—
Outstanding, Sept. 30	11,842	$	0.10	1,842	$	0.59

In connection with the issuance of the $10.0 million secured promissory notes to Oxford in December 2013, we issued a common stock purchase warrant (“warrant”) exercisable for 60 thousand shares of our common stock having an exercise price of $2.52 per share (after giving effect to our one-for-five reverse stock split) with an expiration date in December 2020. These warrants contain a cashless exercise feature (See Note 8).

As part of our July 2017 private placement transaction with Mr. Schutte, we issued a warrant to purchase approx. 1.782 million shares of our common stock. The warrant is immediately exercisable at a price of $0.528 per share and expire five years after issuance (See Note 9).

On June 28, 2019 as part of the changes made to the loan agreements we had with Mr. Schutte, each having an original due date of January 2, 2020, we issued to him a warrant to purchase 10.0 million shares of our common stock exercisable at a price of $0.01 per share and expire five years after issuance (see Note 8). The warrant was assigned and transferred by Mr. Schutte to AD Pharma on June 28, 2019.

SHARE-BASED COMPENSATION EXPENSE

9 Months Ended

Sep. 30, 2019

SHARE-BASED COMPENSATION EXPENSE

SHARE-BASED COMPENSATION EXPENSE

NOTE 12 – SHARE-BASED COMPENSATION EXPENSE

Share-based Compensation

We have four share-based compensation plans covering stock options and RSUs for our employees and directors.

We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. Option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the market price of our common stock on the date of grant, less its exercise cost.

Our share-based compensation expense recognized in the Company’s results of operations from non-cash and cash-portioned instruments issued to our employees and directors comprised the following (in thousands):


	Three months Ended				Nine months Ended
	September 30,				September 30,
	2019		2018		2019		2018
	(in thousands)
Research and development costs:
Stock options	$	2	$	9	$	6	$	33
Restricted stock units		3		7		11		21
Subtotal	$	5	$	16	$	17	$	54

General and administrative costs:
Stock options	$	3	$	14	$	10	$	67
Restricted stock units		40		18		89		69
Subtotal		43	$	32		99	$	136

Total	$	48	$	48	$	116	$	190

Stock Option Award Plans

We maintain various stock option plans. A summary of our stock option plan activity during the nine month periods ending September 30, 2019 and 2018 is shown below:


	Nine Months Ended
	September 30,
	2019			2018
	Number	Weighted			Weighted
	of	Average		Number of	Average
	Options	Exercise		Options	Exercise
	(000’s)	Price		(000’s)	Price
Outstanding, Jan. 1	1,560	$	7.38	1,494	$	12.33
Granted	—		—	—		—
Exercised	—		—	—		—
Forfeited or expired	(182)		(30.83)	(166)		(1.77)
Outstanding, Sept. 30	1,378	$	4.44	1,328	$	8.64
Options exercisable	1,155	$	5.26	1,313	$	8.73

The following table summarizes information about nonvested stock options outstanding at September 30, 2019 (in thousands except price data):


	Number of	Weighted
	Options Not	Average
	Exercisable	Fair Value
Outstanding, Jan. 1, 2019	232	$	0.10
Granted	—		—
Vested	—		—
Forfeited	(9)		(0.10)
Outstanding, Sept. 30, 2019	223	$	0.10

We estimate the option’s fair value on the date of grant using the Black-Scholes option-pricing model. Black-Scholes utilizes assumptions related to expected term, forfeitures, volatility, the risk-free interest rate, the dividend yield (which is assumed to be zero, as we have not paid any cash dividends) and employee exercise behavior. Expected volatilities utilized in the Black-Scholes model are based on the historical volatility of our common stock price. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. The expected life of the grants is derived from historical exercise activity.

The intrinsic value of the option awards which were vested and outstanding at each of September 30, 2019 and 2018 was $0. The total remaining unrecognized compensation cost on unvested option awards outstanding at September 30, 2019 was $4 thousand, and is expected to be recognized in operating expense in varying amounts over the eight months remaining in the requisite service period.

Restricted Stock Unit Award Plans

We have two Restricted Stock Unit Award Plans for our employees and non-employee directors; a 2017 Restricted Stock Unit Award Plan (the “2017 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”). The 2017 RSU Plan was approved by our shareholders in November 2017 and permits the grant of up to 1.5 million shares of our common stock pursuant to awards under the 2017 RSU Plan. The 2014 RSU Plan was approved by shareholders in May 2014 and permits the grant of up to 400 thousand shares of our common stock pursuant to awards under the 2014 RSU Plan. As of September 30, 2019 there are approximately 219 thousand shares available for award under the 2017 RSU Plan and there are no remaining shares available for award under the 2014 RSU Plan.

Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The RSU awards to our non-employee directors allow for them to receive payment in cash upon the RSU award's distribution, instead of an exchange into our common stock, for up to 40% of each RSU award. The portion of the RSU award subject to cash settlement is recorded as a liability in the Company’s balance sheet and to either general and administrative expense or research and development expense while being marked-to-market each reporting period until the award is distributed. The liability was $29 thousand and $11 thousand at September 30, 2019 and December 31, 2018, respectively.

The compensation cost to be incurred by the Company on a granted RSU award without a cash settlement option is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized over the vesting period of the RSU award to either general and administrative expense or research and development expense and recorded as additional paid-in capital.

A summary of the grants under the RSU Plans as of September 30, 2019 and 2018, and for the nine month period then ended consisted of the following (in thousands):


	Nine Months Ended September 30,
	2019		2018
	(in thousands)
		Number of		Number of
	Number	Vested	Number of	Vested
	of RSUs	RSUs	RSUs	RSUs
Outstanding, Jan. 1	951	459	462	262
Granted	333	—	267	—
Distributed	(267)	(267)	(262)	(262)
Vested	—	250	—	200
Forfeited or expired	—	—	(8)	—
Outstanding, Sept. 30	1,017	442	459	200

Information about the award activity under the RSU Plans is as follows:

In December 2017, we awarded 200 thousand RSUs to employees and such RSU awards were fully vested on December 31, 2018. Distribution of these awards and the exchange into common stock will occur in one third amounts on each of January 1, 2020, 2021 and 2022. The employees have the option to pay the par value of the common stock and settle payroll withholding taxes in shares of common stock they would otherwise be receiving resulting in a net share settlement.

In January 2017, we awarded approximately 60 thousand RSUs to each of our non-employee directors. Such awards vested 25% at the end of each calendar quarter during 2017. In January 2018, these awards were distributed and they were exchanged into 214 thousand shares of our common stock while 24 thousand RSUs were settled in cash. There were also 24 thousand RSUs exchanged into common stock from prior year awards.

In January 2018, we awarded approximately 67 thousand RSUs to each of our non-employee directors. Such awards vested 25% at the end of each calendar quarter during 2018. In January 2019, these awards were distributed and they were exchanged into 266 shares of our common stock.

In December 2018, we awarded 492 thousand RSUs to employees and such RSU awards will vested in full on December 31, 2019. Distribution of these awards and the exchange into common stock will occur in one third amounts on each of January 1, 2021, 2022 and 2023. The employees have the option to pay the par value of the common stock and settle payroll withholding taxes in shares of common stock they would otherwise be receiving resulting in a net share settlement.

In January 2019, we awarded approximately 83 thousand RSUs to each of our non-employee directors. Such awards vest 25% at the end of each calendar quarter during 2019. These awards will be distributed and exchanged into common stock will occur in one third amounts on each of January 2020 and up to 40% of the award can be settled in cash.

NET INCOME (LOSS) PER SHARE

9 Months Ended

Sep. 30, 2019

NET INCOME (LOSS) PER SHARE

NET INCOME (LOSS) PER SHARE

NOTE 14 – NET INCOME (LOSS) PER SHARE

Basic earnings (loss) per share (“EPS”) is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to both the vested Restricted Stock Units (“RSUs”) which settle in shares (See Note 12) and the stock warrant exercisable for 10.0 million shares having an exercise price of $0.01 per share (See Note 8). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2019 or 2018 as the Company reported a net loss for the three and nine month periods, or in the event of reporting net income the basic EPS was $0, and including the effects of the common stock equivalents in the diluted EPS calculations would have been antidilutive. The weighted-average common share outstanding diluted computation is not impacted during any period where the exercise price of a stock option, common stock warrant or convertible loan is greater than the average market price of our common stock.

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands except per share data):


	Three months Ended				Nine months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Net income (loss) per share – basic and diluted
Numerator: net income (loss)	$	200	$	(1,095)	$	(3,929)	$	(3,850)
Denominator (weighted):
Common shares		21,300		21,034		21,300		21,033
RSUs – vested		293		134		243		68
Common stock purchase warrant		10,000		—		3,480		—
Basic and diluted weighted average shares outstanding		31,593		21,168		25,023		21,101
Net income (loss) per share – basic and diluted	$	—	$	(0.05)	$	(0.16)	$	(0.18)
Excluded securities (non-weighted):
Common shares issuable:
RSUs – vested and nonvested		542		260		542		260
Stock options – nonvested		1,378		1,328		1,378		1,328
Common stock purchase warrants		1,842		1,842		1,842		1,842
Convertible loan		37,500		—		37,500		—
Total excluded potentially dilutive shares		41,262		3,430		41,262		3,430

DEBT (Tables)

9 Months Ended

Sep. 30, 2019

DEBT

Schedule of debt interest expense

Our debt interest expense for the three and nine month months ended September 30, 2019 and 2018 consisted of the following:


	Three months Ended				Nine months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Interest expense:	(in thousands)				(in thousands)
Fully paid term loan	$	—	$	49	$	—	$	194
Related party term loans		111		29		279		37
Debt discount		—		22		66		46
Debt issue costs		—		3		—		13
Financed insurance premiums		—		2		3		2
Total interest expense	$	111	$	105	$	348	$	292
Less: imputed interest income on related party loan		—		(29)		(13)		(103)
Total interest expense, net	$	111	$	76	$	335	$	189

COMMON STOCK WARRANTS (Tables)

9 Months Ended

Sep. 30, 2019

COMMON STOCK WARRANTS

Schedule Of Common Stock Warrant Activity

Our warrant activity for the nine months ended September 30, 2019 and 2018 consisted of the following (in thousands except price data):


	Nine Months Ended
	September 30,
	2019			2018
		WAvg			WAvg
		Exercise			Exercise
	Number	Price		Number	Price
Outstanding, Jan. 1	1,842	$	0.59	1,842	$	0.59
Issued	10,000		0.01	—		—
Exercised	—		—	—		—
Expired	—		—	—		—
Modification	—		—	—		—
Outstanding, Sept. 30	11,842	$	0.10	1,842	$	0.59

SHARE-BASED COMPENSATION EXPENSE (Tables)

9 Months Ended

Sep. 30, 2019

SHARE-BASED COMPENSATION EXPENSE

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs


	Three months Ended				Nine months Ended
	September 30,				September 30,
	2019		2018		2019		2018
	(in thousands)
Research and development costs:
Stock options	$	2	$	9	$	6	$	33
Restricted stock units		3		7		11		21
Subtotal	$	5	$	16	$	17	$	54

General and administrative costs:
Stock options	$	3	$	14	$	10	$	67
Restricted stock units		40		18		89		69
Subtotal		43	$	32		99	$	136

Total	$	48	$	48	$	116	$	190

Schedule of Share-based Compensation, Stock Option plan activity

We maintain various stock option plans. A summary of our stock option plan activity during the nine month periods ending September 30, 2019 and 2018 is shown below:


	Nine Months Ended
	September 30,
	2019			2018
	Number	Weighted			Weighted
	of	Average		Number of	Average
	Options	Exercise		Options	Exercise
	(000’s)	Price		(000’s)	Price
Outstanding, Jan. 1	1,560	$	7.38	1,494	$	12.33
Granted	—		—	—		—
Exercised	—		—	—		—
Forfeited or expired	(182)		(30.83)	(166)		(1.77)
Outstanding, Sept. 30	1,378	$	4.44	1,328	$	8.64
Options exercisable	1,155	$	5.26	1,313	$	8.73

Schedule of Nonvested stock options outstanding

The following table summarizes information about nonvested stock options outstanding at September 30, 2019 (in thousands except price data):


	Number of	Weighted
	Options Not	Average
	Exercisable	Fair Value
Outstanding, Jan. 1, 2019	232	$	0.10
Granted	—		—
Vested	—		—
Forfeited	(9)		(0.10)
Outstanding, Sept. 30, 2019	223	$	0.10

Schedule of Share-based Compensation, Restricted Stock Units Award Activity

A summary of the grants under the RSU Plans as of September 30, 2019 and 2018, and for the nine month period then ended consisted of the following (in thousands):


	Nine Months Ended September 30,
	2019		2018
	(in thousands)
		Number of		Number of
	Number	Vested	Number of	Vested
	of RSUs	RSUs	RSUs	RSUs
Outstanding, Jan. 1	951	459	462	262
Granted	333	—	267	—
Distributed	(267)	(267)	(262)	(262)
Vested	—	250	—	200
Forfeited or expired	—	—	(8)	—
Outstanding, Sept. 30	1,017	442	459	200

NET INCOME (LOSS) PER SHARE (Tables)

9 Months Ended

Sep. 30, 2019

NET INCOME (LOSS) PER SHARE

Schedule of reconciliation of basic and diluted

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands except per share data):


	Three months Ended				Nine months Ended
	September 30,				September 30,
	2019		2018		2019		2018
Net income (loss) per share – basic and diluted
Numerator: net income (loss)	$	200	$	(1,095)	$	(3,929)	$	(3,850)
Denominator (weighted):
Common shares		21,300		21,034		21,300		21,033
RSUs – vested		293		134		243		68
Common stock purchase warrant		10,000		—		3,480		—
Basic and diluted weighted average shares outstanding		31,593		21,168		25,023		21,101
Net income (loss) per share – basic and diluted	$	—	$	(0.05)	$	(0.16)	$	(0.18)
Excluded securities (non-weighted):
Common shares issuable:
RSUs – vested and nonvested		542		260		542		260
Stock options – nonvested		1,378		1,328		1,378		1,328
Common stock purchase warrants		1,842		1,842		1,842		1,842
Convertible loan		37,500		—		37,500		—
Total excluded potentially dilutive shares		41,262		3,430		41,262		3,430

LICENSE AND COLLABORATION AGREEMENTS (Details) - USD ($) $ in Thousands, shares in Millions				1 Months Ended			3 Months Ended		9 Months Ended
	Jul. 02, 2019	Jun. 28, 2019	Oct. 09, 2015	Mar. 31, 2017	Oct. 31, 2016	Apr. 30, 2014	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
License Development and Commercialization Agreement [Line Items]
Revenue from Contract with Customer, Including Assessed Tax							$ 172	$ 73	$ 285	$ 347
Revenue From Royalty							172	$ 73	$ 285	$ 347
Patents [Member]
License Development and Commercialization Agreement [Line Items]
Payment for Termination						$ 2,000
Schutte \| AD Pharma Agreement
License Development and Commercialization Agreement [Line Items]
Percentage of common stock held		47.50%
Abuse Deterrent Pharma, LLC
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable	$ 350	$ 350
Abuse Deterrent Pharma, LLC \| AD Pharma Agreement
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable		$ 350
Period until which monthly license payment is receivable		18 months							5 years
MainPointe Pharmaceuticals, LLC \| AD Pharma Agreement
License Development and Commercialization Agreement [Line Items]
Waiver of exercise price if exercise of option occurs by certain date		$ 500							$ 500
Period from effective date for exercise of option		5 years
Schutte
License Development and Commercialization Agreement [Line Items]
Aggregate principal of promissory notes and accrued interest		$ 6,000
Debt Conversion, Converted Instrument, Warrants or Options Issued		10.0
Schutte \| AD Pharma Agreement
License Development and Commercialization Agreement [Line Items]
Aggregate principal of promissory notes and accrued interest		$ 6,000
Debt Conversion, Converted Instrument, Warrants or Options Issued		10.0
Zyla
License Development and Commercialization Agreement [Line Items]
Payment for Termination						$ 2,000
Minimum Net Sales Reaching Description									one-time $12.5 million sales-based milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year.
Agreement Termination Notice Description									Zyla may terminate the Zyla Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Zyla's launch of Oxaydo. Termination does not affect a party's rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Zyla Agreement provides for the transition of development and marketing of Oxaydo from Zyla to us, including the conveyance by Zyla to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Zyla's supply of Oxaydo for a transition period.
Revenue from Contract with Customer, Including Assessed Tax			$ 5,000
Proceeds from Milestone Payment On Agreement			$ 2,500
Finite-Lived Intangible Asset, Useful Life						9 years 8 months 12 days
Finite-Lived Intangible Assets, Amortization Expense, Year Two							208		$ 208
FiniteLived Intangible Assets Amortization Expense Quarter							$ 52		$ 52
MainPointe
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable				$ 2,500
Licensing Agreement, Royalty Percentage				7.50%
License Agreement Option Products Description				In addition, MainPointe has the option to add to the MainPointe Agreement certain additional products, or Option Products, containing PSE and utilizing the Impede technology for a fee of $500 thousand per product (for all product strengths). Such Option Products include the product candidate Loratadine with pseudoephedrine. If the territory has been expanded prior to the exercise of a product option, the option fee will be increased to $750 thousand per product. If the territory is expanded after the payment of the $500 thousand product option fee, a one-time $250 thousand fee will be due for each product. If a third party is interested in developing or licensing rights to an Option Product, MainPointe must exercise its option for that product or its option rights for such product will terminate.
MainPointe \| UNITED KINGDOM
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable				$ 1,000
MainPointe \| JAPAN
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable				500
MainPointe \| South Korea [Member]
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable				$ 250
Kempharm Agreement [Member]
License Development and Commercialization Agreement [Line Items]
Monthly license payment receivable					$ 3,500
Kempharm Agreement [Member] \| Minimum
License Development and Commercialization Agreement [Line Items]
Additional Upfront Payment Receivable					$ 1,000

ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
ACCRUED EXPENSES
Cost sharing expenses under license agreement	$ 330	$ 237
Other fees and services	19	36
Payroll, payroll taxes and benefits	9	6
Professional services	244	132
Financed premiums on insurance policies	18	102
Clinical, non-clinical and regulatory services	50	63
Property taxes	7	7
Franchise taxes	8	13
Total	$ 685	$ 596

DEBT - Additional Information (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		1 Months Ended		3 Months Ended		9 Months Ended
	Jun. 28, 2019	Oct. 31, 2018	Jan. 31, 2015	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Jun. 27, 2019	Dec. 31, 2013
Debt Instrument [Line Items]
Debt instrument principal amount									$ 10,000
Proceeds from Issuance of Long-term Debt		$ 1,800
Debt instrument, interest rate, stated percentage								10.16%	13.35%
Debt instrument, fee amount				$ 50		$ 50
Gain (Loss) on Extinguishment of Debt	$ (2,600)	296		0	$ 0	(2,600)	$ 0
Debt consulting placement fee						100
Deferred debt issue costs				$ 0	$ 3	0	13
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Repayments of Debt							$ 1,719
Debt Instrument, Periodic Payment						$ 260
Debt Instrument, Interest Rate, Effective Percentage				10.16%		10.16%
Related party loans made to Company	$ 5,000			$ 5,000		$ 5,000
Term Loan [Member]
Debt Instrument [Line Items]
Deferred debt issue costs						231
Schutte Note [Member]
Debt Instrument [Line Items]
Debt instrument principal amount								$ 5,000
Proceeds from Issuance of Long-term Debt	725
Aggregate principal of promissory notes and accrued interest	6,000
Debt instrument, interest rate, stated percentage								7.50%
Gain (Loss) on Extinguishment of Debt	$ (2,600)
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.01
Debt Conversion, Converted Instrument, Shares Issued	37,500
Debt Conversion, Converted Instrument, Warrants or Options Issued	10,000
Share Price	$ 0.16
Related party loans made to Company								$ 650
Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage									8.35%
Oxford Term Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument principal amount								$ 185
Repayments of Debt		$ 1,500
Maximum
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 7.98
Minimum
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.52
Common stock purchase warrants
Debt Instrument [Line Items]
Debt instrument unamortized discount				$ 400		$ 400
Warrants to purchase common stock				60		60
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.52		$ 2.52
Warrants, expiry date						December 27, 2020
Additions To Debt Instrument Unamortized Discount			$ 33

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended			3 Months Ended		6 Months Ended	9 Months Ended
	Jul. 02, 2019	Jun. 28, 2019	Oct. 31, 2018	Jul. 31, 2017	Mar. 31, 2017	Sep. 30, 2019	Sep. 30, 2018	Jun. 27, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2013
Related Party Transaction [Line Items]
Fixed interest rate								10.16%			13.35%
Number Of Common Stock Need To Hold To Designate As Director				600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.01
Proceeds from Issuance of Long-term Debt			$ 1,800
Class Of Warrants Or Rights, Expiry Period				5 years
Royalty revenues						$ 172	$ 73		$ 285	$ 347
MainPointe
Related Party Transaction [Line Items]
Proceeds from License Fees Received					$ 2,500
Asset Transferred, License Agreement					$ 309
Licensing Agreement, Royalty Percentage					7.50%
MainPointe \| Royalty [Member]
Related Party Transaction [Line Items]
Royalty revenues						3	$ 6		15	$ 14
Investor [Member]
Related Party Transaction [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.528
Investor [Member] \| Private Placement [Member]
Related Party Transaction [Line Items]
Sale of Stock, Consideration Received on Transaction				$ 4,000
Sale of Stock, Number of Shares Issued in Transaction				8,912,655
Sale of Stock, Price Per Share				$ 0.4488
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.528
Sale Of Stock, Issue Price Description				85%
Warrants Not Settleable in Cash, Fair Value Disclosure						$ 495			495
Proceeds from Issuance of Warrants									$ 4,000
Schutte
Related Party Transaction [Line Items]
Aggregate principal of promissory notes and accrued interest		$ 6,000
Fixed interest rate		7.50%
Share Price		$ 0.16
Debt Conversion, Converted Instrument, Warrants or Options Issued		10,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.01
Debt Conversion, Converted Instrument, Shares Issued		37,500,000
Proceeds from Issuance of Long-term Debt		$ 725						$ 650
Abuse Deterrent Pharma, LLC
Related Party Transaction [Line Items]
Proceeds from License Fees Received	$ 350	$ 350

COMMON STOCK WARRANTS - Warrant Activity (Details) - Common stock purchase warrants - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Number of Options
Number of Options Outstanding, beginning	1,842	1,842
Number of Options, Issued	10,000	0
Number of Options, Exercised	0	0
Number of Options, Expired	0	0
Number of Options, Modification	0	0
Number of Options Outstanding, ending	11,842	1,842
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$ 0.59	$ 0.59
Weighted Average Exercise Price, Issued	0.01	0
Weighted Average Exercise Price, Exercised	0	0
Weighted Average Exercise Price, Expired	0	0
Weighted Average Exercise Price, Modification	0	0
Weighted Average Exercise Price, ending	$ 0.10	$ 0.59

SHARE-BASED COMPENSATION EXPENSE - Summary of Information about Non Vested Stock Options (Details) - Non Vested Stock Options [Member] shares in Thousands	9 Months Ended
	Sep. 30, 2019 $ / shares shares
Summary Of Information About Non Vested Stock Options Disclosure [Line Items]
Outstanding, beginning \| shares	232
Granted \| shares	0
Vested \| shares	0
Forfeited \| shares	(9)
Outstanding, ending \| shares	223
Outstanding beginning, Weighted Average Fair Value \| $ / shares	$ 0.10
Granted, Weighted Average Fair Value \| $ / shares	0
Vested, Weighted Average Fair Value \| $ / shares	0.00
Forfeited, Weighted Average Fair Value \| $ / shares	(0.10)
Outstanding ending, Weighted Average Fair Value \| $ / shares	$ 0.10

SHARE-BASED COMPENSATION EXPENSE- Additional Information (Details) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended					3 Months Ended		9 Months Ended
	Jan. 31, 2019	Dec. 31, 2018	Jan. 31, 2018	Dec. 31, 2017	Jan. 31, 2017	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Nov. 30, 2017	May 31, 2014
Employee Benefit Plans Disclosure [Line Items]
Aggregate intrinsic value of the option awards vested						$ 0	$ 0	$ 0	$ 0
Unrecognized compensation cost on unvested option awards outstanding						4		4
Allocated Share-based Compensation Expense						48	$ 48	$ 116	$ 190
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition								8 months
Restricted stock units \| Director [Member]
Employee Benefit Plans Disclosure [Line Items]
Deferred Compensation Arrangement with Individual, Recorded Liability		$ 11				$ 29		$ 29
Restricted Stock Award Plan
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant						219		219
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					60
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			25.00%		25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description								stock, for up to 40%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized										1,500
Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Grants In Period		492	67	200
Restricted Stock Award Plan \| January 4, 2016 Award Distributed [Member]
Employee Benefit Plans Disclosure [Line Items]
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution	83
Restricted Stock Award Plan \| Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage	25.00%
2014 Restricted Stock Unit Award Plan [Member]
Employee Benefit Plans Disclosure [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant											400

NET INCOME (LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended		12 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Net income (loss) per share - basic and diluted
Numerator: net income (loss)	$ 200	$ (3,341)	$ (788)	$ (1,095)	$ (1,261)	$ (1,494)	$ (3,929)	$ (3,850)	$ (3,840)
Denominator (weighted):
Common shares	21,300			21,034			21,300	21,033
RSUs - vested	293			134			243	68
Common stock purchase warrants	10,000						3,480
Basic and diluted weighted average shares outstanding	31,593			21,168			25,023	21,101
Net income (loss) per share - basic and diluted				$ (0.05)			$ (0.16)	$ (0.18)
Common stock issuable:
Total excluded potentially dilutive shares	41,262			3,430			41,262	3,430
Restricted stock units
Common stock issuable:
Total excluded potentially dilutive shares	542			260			542	260
Stock options
Common stock issuable:
Total excluded potentially dilutive shares	1,378			1,328			1,378	1,328
Common stock purchase warrants
Common stock issuable:
Total excluded potentially dilutive shares	1,842			1,842			1,842	1,842
Convertible loan
Common stock issuable:
Total excluded potentially dilutive shares	37,500						37,500

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
RECENT ACCOUNTING PRONOUNCEMENTS	Sep. 30, 2019
RECENT ACCOUNTING PRONOUNCEMENTS
RECENT ACCOUNTING PRONOUNCEMENTS	NOTE 2 – RECENT ACCOUNTING PRONOUNCEMENTS New accounting standards which have been adopted on or before September 30, 2019 Leases In February 2016, the FASB issued ASU 2016-02, Leases (ASC 842), which establishes a comprehensive new lease accounting model. The new standard will require most leases (with the exception of leases with terms of one year or less) to be recognized on the balance sheet as a lease liability with a corresponding right-of-use asset. Leases will be classified as an operating lease or a financing lease. The classification of the lease will affect the pattern of expense recognition in the income statement such that operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The standard also requires disclosures to help investors and other financial statement users better understand the amount, timing and uncertainty of cash flows arising from leases. In July 2018, the FASB issued ASU No. 2018-10, "Codification Improvements to Topic 842, Leases" (ASU 2018-10), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, "Leases (Topic 842)-Targeted Improvements" (ASU 2018-11), which addressed implementation issues related to the new lease standard. These and certain other lease-related ASUs have generally been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in Accounting Standards Codification Topic 840, Leases (ASC 840). The Company adopted ASC 842 using the modified retrospective transition approach during Q1 2019, which allows the Company to not adjust the comparative periods presented. The Company has elected to adopt the package of transition practical expedients and, therefore, has not reassessed whether existing or expired contracts contain a lease or the lease classification for existing or expired. The Company did not elect the practical expedient to use hindsight for leases existing at the adoption date. Upon adoption, operating leases would be reported on the balance sheet as a gross-up of assets and liabilities, however the Company has elected, as an accounting policy, to not recognize ROU assets and lease liabilities for all short-term leases that have a lease term of 12 months or less. The adoption of ASC 842 did not have an impact on the Company’s financial statements as the Company has no leases with term of more than 12 months.

RESEARCH AND DEVELOPMENT ACTIVITIES	9 Months Ended
RESEARCH AND DEVELOPMENT ACTIVITIES	Sep. 30, 2019
RESEARCH AND DEVELOPMENT ACTIVITIES
RESEARCH AND DEVELOPMENT ACTIVITIES	NOTE 5 – RESEARCH AND DEVELOPMENT ACTIVITIES Research and Development (“R&D”) costs include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research and investigative sites, and other activities. Internal R&D activity costs can include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, formulation work, depreciation, salaries, benefits, insurance and share-based compensation expenses. CRO activity costs can include preclinical laboratory experiments and clinical trial studies. Other activity costs can include regulatory consulting, regulatory legal counsel, cost of acquiring, developing and manufacturing pre-clinical trial materials, costs of manufacturing scale-up, and cost sharing expenses under license agreements. Internal R&D costs and other activity costs are charged to expense as incurred. We make payments to CROs based on agreed upon terms and may include payments in advance of a study starting date. Payments in advance will be reflected in the financial statements as prepaid expenses. We review and charge to expense the amounts for CRO costs and clinical trial study costs based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO to us. The accrued CRO costs are subject to revisions by us as the study progresses towards completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known to us. We did not have any remaining obligations under cancelable arrangements, nor did we have any prepaid CRO costs or prepaid clinical trial study expenses at September 30, 2019 or December 31, 2018.

FAIR VALUE MEASUREMENTS	9 Months Ended
FAIR VALUE MEASUREMENTS	Sep. 30, 2019
FAIR VALUE MEASUREMENTS
FAIR VALUE MEASUREMENTS	NOTE 11 – FAIR VALUE MEASUREMENTS The Company’s financial instruments consist primarily of cash and cash equivalents, receivables from trade, royalties and collaboration, trade accounts payable, and our long-term debt. The carrying amounts of these financial instruments, other than our debt, are representative of their respective fair values due to their relatively short maturities. On June 28, 2019, we restructured the $5.0 million related party loan and reported the debt using fair value for the changes to the loan resulting in the recognizing a $2.6 million loss on debt extinguishment.

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2019
INCOME TAXES
INCOME TAXES	NOTE 13 – INCOME TAXES We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax basis of assets and liabilities and are accounted for using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets reflect the tax effects of net operating losses (“NOLs”), tax credit carryovers, and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The most significant item of our deferred tax assets is derived from our Federal NOLs. We have approximately $171.8 million gross Federal NOLs at December 31, 2018 (of which approximately $167.7 million were generated prior to 2018). Because we believe the ability for us to use these NOLs generated prior to January 1, 2018 to offset any future taxable income is severely limited as prescribed under Internal Revenue Code (“IRC”) Section 382, we had estimated and recorded an amount for the likely limitation to our deferred tax asset in the fourth quarter of 2017, thereby reducing the aggregate estimated benefit of the Federal NOLs available to us of approximately $1.0 million at December 31, 2017. We believe the gross Federal NOL benefit we generated prior to January 1, 2018 to offset taxable income is less than $150 thousand annually. As prescribed under Internal Revenue Code, any unused Federal NOL benefit from the annual limitation can be accumulated and carried forward to the subsequent year and will expire if not used in accordance with the NOL carried forward term of 20 years or 2037, if generated before 2018 and Federal NOLs generated after 2017 can be carried forward indefinitely. Future common stock transactions, such as the exercise of common stock purchase warrants or the conversion of debt into common stock, may cause another qualifying event under IRC 382 which may further limit our utilization of our NOLs. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At both September 30, 2019 and December 31, 2018, all our remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of NOL carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized.

COMMITMENTS AND CONTINGENCIES	9 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2019
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	NOTE 15 – COMMITMENTS AND CONTINGENCIES Reglan®/Metoclopramide Litigation Halsey Drug Company, as predecessor to us, was named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L‑3865‑10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC‑10‑004631. In addition, we were served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide. None of the plaintiffs in the lawsuits filed to date have confirmed that they ingested any of the generic metoclopramide manufactured by us. We discontinued manufacture and distribution of generic metoclopramide more than 20 years ago. All of these lawsuits have been effectively dismissed with the exception of less than ten pending Philadelphia cases that we expect will be finally dismissed without the need for any action by us. We expect that the Court will finally dismiss the small number of remaining Pennsylvania-based cases against us with prejudice by the end of the first quarter of 2020. Legal fees related to this matter have been covered by our insurance carrier. Based upon the current status and evaluation, we have not accrued for any potential loss related to these matters as of September 30, 2019.

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
CONSOLIDATED BALANCE SHEETS
Accumulated amortization, deferred finance costs	$ 1,138	$ 983
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	21,300	21,034
Common stock, shares outstanding	21,300	21,034

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Total	$ 2,512	$ 2,512
Less: accumulated depreciation	(1,957)	(1,906)
Net property, plant and equipment	555	606
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	1,273	1,273
Scientific Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	598	598
Computer Hardware and Software [Member]
Property, Plant and Equipment [Line Items]
Total	107	107
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	275	275
Land and Improvements [Member]
Property, Plant and Equipment [Line Items]
Total	162	162
Other Personal Property [Member]
Property, Plant and Equipment [Line Items]
Total	70	70
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Total	$ 27	$ 27

DEBT - Interest Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
DEBT - Interest Expense (Details) - USD ($) $ in Thousands	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
DEBT
Fully paid term loan	$ 0	$ 49	$ 0	$ 194
Related party term loans	111	29	279	37
Debt discount	0	22	66	46
Debt issue costs	0	3	0	13
Financed insurance premiums	0	2	3	2
Total interest expense	111	105	348	292
Less: imputed interest income on related party loan	0	(29)	(13)	(103)
Total interest expense, net	$ 111	$ 76	$ 335	$ 189

FAIR VALUE MEASUREMENTS (Detail) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended		9 Months Ended
FAIR VALUE MEASUREMENTS (Detail) - USD ($) $ in Thousands	Jun. 28, 2019	Oct. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
FAIR VALUE MEASUREMENTS
Related party loan	$ 5,000		$ 5,000		$ 5,000
Loss on debt extinguishment	$ (2,600)	$ 296	$ 0	$ 0	$ (2,600)	$ 0

SHARE-BASED COMPENSATION EXPENSE - Stock Option plan activity (Details) - Stock Option Plan [Member] - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	1,560	1,494
Number of Options, Forfeited or expired	(182)	(166)
Number of Options Outstanding, ending	1,378	1,328
Number of Options exercisable	1,155	1,313
Weighted Average Exercise Price, beginning	$ 7.38	$ 12.33
Weighted Average Exercise Price, Forfeited or expired	(30.83)	(1.77)
Weighted Average Exercise Price, ending	4.44	8.64
Weighted Average Exercise Price, Options exercisable	$ 5.26	$ 8.73

SHARE-BASED COMPENSATION EXPENSE - Summary of RSU Plan (Details) - shares shares in Thousands	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Restricted Stock Units [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	951	462
Granted	333	267
Distributed	(267)	(262)
Forfeited or expired		(8)
Outstanding, ending	1,017	459
Vested Restricted Stock Units (RSUs) [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	459	262
Distributed	(267)	(262)
Vested	250	200
Outstanding, ending	442	200

INCOME TAXES (Details) - USD ($) $ in Thousands	12 Months Ended
INCOME TAXES (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Sep. 30, 2019
INCOME TAXES
Federal NOLs	$ 167,700		$ 171,800
State income tax benefits		$ 1,000
Operating Loss Carryforwards, Expiration Term	20 years
Operating Loss Carry Forwards Expiration Year	2037
Tax Credit Carryforward, Amount	$ 150